Q3 2024 Holdings
Filed 2024-11-14 | 82 holdings | $8.7B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Ascendis Pharma A/S(ASND) | SH | 04351P101 | $1.4B | 9,710,428 | 16.7% |
| Vaxcyte Inc(PCVX) | SH | 92243G108 | $992.9M | 8,689,190 | 11.4% |
| Janux Therapeutics Inc(JANX) | SH | 47103J105 | $416.4M | 9,165,652 | 4.8% |
| Legend Biotech Corp(LEGN) | SH | 52490G102 | $365.8M | 7,506,934 | 4.2% |
| Rhythm Pharmaceuticals Inc(RYTM) | SH | 76243J105 | $318.8M | 6,084,412 | 3.7% |
| Avidity Biosciences Inc(RNA) | SH | 05370A108 | $289.4M | 6,300,408 | 3.3% |
| Tyra Biosciences Inc(TYRA) | SH | 90240B106 | $244.9M | 10,416,609 | 2.8% |
| Evolent Health Inc(EVH) | SH | 30050B101 | $240.8M | 8,514,862 | 2.8% |
| Edgewise Therapeutics Inc(EWTX) | SH | 28036F105 | $237.8M | 8,909,091 | 2.7% |
| Biogen Inc(BIIB) | SH | 09062X103 | $229.6M | 1,184,456 | 2.6% |
| Dyne Therapeutics Inc(DYN) | SH | 26818M108 | $229.2M | 6,381,144 | 2.6% |
| Rxsight Inc(RXST) | SH | 78349D107 | $193.6M | 3,916,825 | 2.2% |
| Bicara Therapeutics Inc(BCAX) | SH | 055477103 | $177.2M | 6,955,993 | 2.0% |
| Climb BIO Inc(CLYM) | SH | 28658R106 | $159.9M | 31,419,267 | 1.8% |
| ARS Pharmaceuticals Inc(SPRY) | SH | 82835W108 | $157.5M | 10,860,977 | 1.8% |
| Arcellx Inc(ACLX) | SH | 03940C100 | $154.6M | 1,851,479 | 1.8% |
| Artiva Biotherapeutics Inc(ARTV) | SH | 04317A107 | $152.2M | 9,853,302 | 1.8% |
| Wave Life Sciences LTD(WVE) | SH | Y95308105 | $149.3M | 18,202,009 | 1.7% |
| Geron Corp(GERN) | SH | 374163103 | $146.6M | 32,285,755 | 1.7% |
| Verona Pharma PLC(VRNA) | SH | 925050106 | $144.1M | 5,009,653 | 1.7% |
| Newamsterdam Pharma Co NV(NAMS) | SH | N62509109 | $133.9M | 8,064,000 | 1.5% |
| Apogee Therapeutics Inc(APGE) | SH | 03770N101 | $115.2M | 1,961,863 | 1.3% |
| DAY One Biopharmaceuticals I(DAWN) | SH | 23954D109 | $109.7M | 7,871,721 | 1.3% |
| 89Bio Inc(ETNBGBP) | SH | 282559103 | $104.9M | 14,175,398 | 1.2% |
| Recursion Pharmaceuticals(RXRX) | SH | 75629V104 | $101.4M | 15,384,615 | 1.2% |
| Lenz Therapeutics Inc(LENZ) | SH | 52635N103 | $99.2M | 4,178,823 | 1.1% |
| Pepgen Inc(PEPG) | SH | 713317105 | $91.4M | 10,689,545 | 1.1% |
| Axsome Therapeutics Inc(AXSM) | SH | 05464T104 | $89.9M | 1,000,000 | 1.0% |
| Structure Therapeutics Inc(GPCR) | SH | 86366E106 | $83.2M | 1,896,772 | 1.0% |
| Tourmaline BIO Inc(TRML) | SH | 89157D105 | $65.3M | 2,538,925 | 0.8% |
| Dianthus Therapeutics Inc(DNTH) | SH | 252828108 | $63.9M | 2,333,000 | 0.7% |
| Mineralys Therapeutics Inc(MLYS) | SH | 603170101 | $58.7M | 4,850,984 | 0.7% |
| Acrivon Therapeutics Inc(ACRV) | SH | 004890109 | $58.4M | 8,340,508 | 0.7% |
| Astria Therapeutics Inc(CATBUSD) | SH | 04635X102 | $56.2M | 5,105,213 | 0.6% |
| 4D Molecular Therapeutics in(FDMT) | SH | 35104E100 | $55.1M | 5,098,211 | 0.6% |
| CG Oncology Inc(CGON) | SH | 156944100 | $52.7M | 1,397,433 | 0.6% |
| Bicycle Therapeutics PLC(BCYC) | SH | 088786108 | $51.0M | 2,253,000 | 0.6% |
| Nkarta Inc(NKTX) | SH | 65487U108 | $48.8M | 10,805,129 | 0.6% |
| Bioage Labs Inc(BIOA) | SH | 09077V100 | $46.0M | 2,210,589 | 0.5% |
| GH Research PLC(GHRS) | SH | G3855L106 | $44.7M | 6,686,689 | 0.5% |
| Praxis Precision Medicines I(PRAX) | SH | 74006W207 | $43.8M | 761,955 | 0.5% |
| Ideaya Biosciences Inc(IDYA) | SH | 45166A102 | $42.7M | 1,347,252 | 0.5% |
| Larimar Therapeutics Inc(LRMR) | SH | 517125100 | $39.6M | 6,045,351 | 0.5% |
| MBX Biosciences Inc(MBX) | SH | 55287L101 | $39.3M | 1,511,334 | 0.5% |
| Acumen Pharmaceuticals Inc(ABOS) | SH | 00509G209 | $37.0M | 14,932,063 | 0.4% |
| Fulcrum Therapeutics Inc(FULC) | SH | 359616109 | $36.5M | 10,229,099 | 0.4% |
| Iteos Therapeutics Inc(5E7) | SH | 46565G104 | $32.5M | 3,184,711 | 0.4% |
| Solid Biosciences Inc(SLDB) | SH | 83422E204 | $30.2M | 4,330,446 | 0.3% |
| C4 Therapeutics Inc(CCCC) | SH | 12529R107 | $27.8M | 4,878,000 | 0.3% |
| Enliven Therapeutics Inc(ELVN) | SH | 29337E102 | $27.1M | 1,061,233 | 0.3% |